Real-world effectiveness and safety of omalizumab in patients with uncontrolled severe allergic asthma from the Czech Republic

Real-world effectiveness and safety of omalizumab in patients with uncontrolled severe allergic asthma from the Czech Republic

Bibliographic Details
Main Authors:	Olga Růžičková Kirchnerová, Tomáš Valena, Jakub Novosad, Milan Teřl
Format:	Article
Language:	English
Published:	Termedia Publishing House 2018-06-01
Series:	Advances in Dermatology and Allergology
Subjects:	observational registry omalizumab real-world study allergic asthma asthma control exacerbations
Online Access:	https://www.termedia.pl/Real-world-effectiveness-and-safety-of-omalizumab-in-patients-with-uncontrolled-severe-allergic-asthma-from-the-Czech-Republic,7,33119,1,1.html

Similar Items

Effect of individual allergen sensitization on omalizumab treatment outcomes in patients with severe allergic asthma determined using data from the Czech Anti-IgE Registry
by: Petr Vaník, et al.
Published: (2020-09-01)

Omalizumab Treatment in Patients with Severe Allergic Asthma
by: Tuğba Songül Tat, et al.
Published: (2017-09-01)

The effect of omalizumab treatment on severe allergic asthma and allergic comorbidities: real-life experience from the Czech Anti-IgE Registry
by: Beáta Hutyrová, et al.
Published: (2018-07-01)

Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study
by: Giorgio Walter Canonica, et al.
Published: (2018-11-01)

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
by: S. M. Snelder, et al.
Published: (2017-07-01)

Omalizumab Treatment for Severe Atopic Asthma in a Real World Montréal Cohort
by: David Haile-Meskale, et al.
Published: (2020-07-01)

Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis
by: Enrico Heffler, et al.
Published: (2020-06-01)

Cost-effectiveness of omalizumab in real world uncontrolled allergic asthma patients
by: A. Arrobas, et al.
Published: (2021-03-01)

Real-World Observational Study on the Characteristics and Treatment Patterns of Allergic Asthma Patients Receiving Omalizumab in Canada
by: Lee JK, et al.
Published: (2020-04-01)

A review of omalizumab for the management of severe asthma
by: Lin CH, et al.
Published: (2016-07-01)

Serum periostin levels in asthma patients in relation to omalizumab therapy and presence of chronic rhinosinusitis with nasal polyps
by: Jakub Novosad, et al.
Published: (2020-05-01)

Respiratory viral infections and asthma exacerbations: new opportunities of omalizumab
by: R. S. Fassakhov
Published: (2020-11-01)

Omalizumab Effectiveness in Severe Allergic Asthma with Multiple Allergic Comorbidities: A Post-Hoc Analysis of the STELLAIR Study
by: Just J, et al.
Published: (2021-09-01)

Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy
by: Hiroshi Odajima, et al.
Published: (2015-10-01)

Effects of Omalizumab Treatment on Some Biomarkers in Severe Allergic Asthma Patients
by: Seda Tural Önür, et al.
Published: (2017-08-01)

The role of omalizumab in the treatment of adults with severe allergic asthma
by: Sabina Škrgat Kristan
Published: (2013-02-01)

Effectiveness of omalizumab in children and adolescents with uncontrolled allergic asthma: a case series from Poland
by: Anna Sztafińska, et al.
Published: (2021-07-01)

FENOMA Study: Achieving Full Control in Patients with Severe Allergic Asthma
by: Cabrejos S, et al.
Published: (2020-05-01)

Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study
by: Christian Domingo, et al.
Published: (2017-02-01)

Omalizumab: an anti-immunoglobulin E antibody for the treatment of allergic respiratory diseases
by: J. Bousquet, et al.
Published: (2008-04-01)

Near-fatal asthma responsive to mepolizumab after failure of omalizumab and bronchial thermoplasty
by: Menzella F, et al.
Published: (2017-11-01)

Real-life long-term safety and effectiveness of omalizumab in Japanese pediatric patients with severe allergic asthma: A post-marketing surveillance
by: Noriko Nakamura, et al.
Published: (2021-07-01)

The effectiveness of target therapy in patients with severe allergic asthma
by: O V Skorokhodkina, et al.
Published: (2019-12-01)

Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US
by: Zafar Zafari, et al.
Published: (2018-01-01)

Patient characteristics that can predict response to omalizumab an (Anti-IgE Antibody) for achieving better control of asthmatic patients
by: Nancy M. Abdelaty
Published: (2012-07-01)

The Long-Term Effectiveness of Omalizumab in Adult Patients with Severe Allergic Asthma: Continuous Treatment Versus Boosting Treatment
by: Wei-Chang Huang, et al.
Published: (2021-02-01)

Improvement of quality of life in patients with concomitant allergic asthma and atopic dermatitis: one year follow-up of omalizumab therapy
by: Velling P, et al.
Published: (2011-09-01)

A Pharmaco-Economic Analyzis of Treating Severe Uncontrolled Child Asthma with Omalizumab — Actual Russian Clinical Practice Data
by: A. S. Kolbin, et al.
Published: (2016-11-01)

Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study
by: Canonica GW, et al.
Published: (2020-01-01)

Pediatric severe asthma: a case series report and perspectives on anti-IgE treatment
by: Virginia Mirra, et al.
Published: (2018-02-01)

Benefits of omalizumab on anxiety and depression in patients with severe asthma
by: Fatih Uzer, et al.
Published: (2018-05-01)

The Long-Term Omalizumab Therapy in Children with Severe Persistent Uncontrolled Asthma: Evaluation of the Outcomes According to the Data of the Hospital Patient Registry
by: Elena A. Vishneva, et al.
Published: (2018-05-01)

Omalizumab versus ‘Usual Care’: Results from a Naturalistic Longitudinal Study in Routine Care
by: Wittchen, Hans-Ulrich, et al.
Published: (2013)

Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy
by: R. Buhl
Published: (2007-09-01)

Long-term safety, efficacy, pharmacokinetics and pharmacodynamics of omalizumab in children with severe uncontrolled asthma
by: Hiroshi Odajima, et al.
Published: (2017-01-01)

The impact of moderate and severe asthma exacerbations on quality of life: a post hoc analysis of randomised controlled trial data
by: Andrew Briggs, et al.
Published: (2021-01-01)

Chronic rhinosinusitis with and without nasal polyps and asthma: Omalizumab improves residual anxiety but not depression
by: Florian Vogt, et al.
Published: (2021-03-01)

Analysis of the Comorbidity of Bronchial Asthma and Allergic Rhinitis by Questionnaire in 10,009 Patients
by: Kohei Yamauchi, et al.
Published: (2009-01-01)

Cost-effectiveness of fractional exhaled nitric oxide (FeNO) measurement in predicting response to omalizumab in asthma
by: Brooks EA, et al.
Published: (2019-04-01)

Omalizumab in children with severe allergic disease: a case series
by: Giuseppe Crisafulli, et al.
Published: (2019-01-01)